Tag: hypertension

ultrasound renal denervation

Ultrasound renal denervation meets primary efficacy endpoint in RADIANCE II study

ReCor Medical and Otsuka Medical Devices have announced that the RADIANCE II US Food and Drug Administration (FDA) investigational device exemption (IDE) pivotal trial...

SoniVie announces successful procedure with Tivus system on first patient enrolled...

SoniVie today announced that on 30 May this year the first patient was treated with its renal artery denervation Tivus therapeutic intravascular ultrasound technology, as...

SoniVie receives FDA IDE approval for pilot study to treat hypertension...

SoniVie recently announced that on 5 May 2022 the US Food and Drug Administration (FDA) granted investigational device exemption (IDE) approval for its REDUCED1...

SyMap Medical completes enrolment of SMART study for treatment of uncontrolled...

SyMap Medical has announced that it has completed enrolment of the SMART study, which will evaluate the safety and efficacy of targeted renal denervation...

Medtronic unveils data on hypertension treatment preferences, launches SPYRAL AFFIRM study

Medtronic today announced findings from a new study of patient preferences for the treatment of hypertension. The findings are set to be presented during...

SCAI releases proceedings from expert consensus roundtable on renal denervation treatment...

The Society for Cardiovascular Angiography and Interventions (SCAI) has released a proceedings document outlining the possible role of renal denervation (RDN) as a therapeutic...

ACC 2021: Long-term blood pressure control the “holy grail” for renal...

 Ajay Kirtane (New York, USA) talks to Renal Interventions about the RADIANCE-HTN TRIO trial which compared renal denervation with a sham procedure to see...
ultrasound renal denervation

ACC.21: Ultrasound renal denervation shown to reduce blood pressure in resistant...

Ultrasound-based endovascular renal denervation can successfully reduce systolic blood pressure in patients with medication-resistant hypertension, as demonstrated by the results of a late-breaking clinical...
brattea renal denervation

Renal denervation firm Brattea completes US$20 million Series B+ funding round

Shanghai-based renal denervation (RDN) company Brattea has announced the successful completion of a Series B+ funding round worth more than US$20 million led by...